Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CDC”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 415 records · Page 23Linked to original sources
PubMed1984

Occurrence of hepatitis A, B, and non-A/non-B in the United States. CDC sentinel county hepatitis study I.

To determine the relative occurrence of hepatitis A, B, and non-A/non-B in the United States, serum samples and epidemiologic data were collected from patients with hepatitis in five selected counties. Overall, 41, 33, and 26 percent of the patients had hepatitis A, hepatitis B, and hepatitis non-A/non-B, respectively. The incidence, especially of hepatitis A, varied considerably. All three types of hepatitis occurred more frequently in those 15 to 44 years of age. Hepatitis A predominated in those less than 15 years of age and non-A/non-B predominated in those older than 44 years. There was a male predominance (65 to 62 percent) for hepatitis A and hepatitis B, but non-A/non-B occurred equally in both sexes. There was no seasonal pattern for any type. Risk factors for hepatitis A were previous contact with a patient with hepatitis (26 percent), homosexual (male) preference (15 percent), and day-care center contact (11 percent). For hepatitis B, risk factors included drug use (26 percent), previous contact with an infected person (22 percent), homosexual preference (12 percent), and a health-care occupation (12 percent). For hepatitis non-A/non-B, risk factors included drug use (16 percent), transfusion (12 percent), and previous contact with an infected person (12 percent). Previous hospitalization appeared to be a risk factor for both hepatitis B and hepatitis non-A/non-B.

Adolescent↗
PubMed1990

Legal implications of OSHA and CDC regulations.

The epidemic of acquired immunodeficiency syndrome has initiated a number of regulations, at both the federal and state level, that impact directly on the practice of dentistry. During the past 5 to 6 years, guidelines have been published that specifically and generally state those procedures which should be implemented in the dental practice with regard to infectious disease control. However, confusion remains regarding these procedural guidelines and the differences that exist between municipal, state, and federal regulations. The ensuing discussion (1) reviews the historical background of the guidelines, (2) reflects on the current Occupational Safety and Health Administration guidelines as they relate to the dental practice, (3) summarizes the role of the regulatory agencies, (4) discusses federal and state statutes that have impact on the dental practitioner, and (5) describes the possible legal implications that these regulations may have on the dental practice.

Acquired Immunodeficiency Syndrome↗
PubMed1992

Isolation and characterization of a cdc 2 cDNA from Dictyostelium discoideum.

A cdc2 homologous sequence was amplified from Dictyostelium discoideum by the polymerase chain reaction and used to isolate several cDNA clones. The amino acid sequence encoded by these cDNAs exhibited approx. 60% identity to the Cdc2 proteins of other species. A cDNA containing the entire coding sequence complemented the temperature sensitive cdc28 mutant of Saccharomyces cerevisiae, although growth of the transformants was slow and limited. Southern blot analysis of restriction digests under high stringency conditions provided evidence that Dictyostelium contains a single cdc2 gene, although at lower stringency multiple fragments were detected, suggesting the existence of a cdc2 gene family. Northern blot analysis of RNA from different stages of Dictyostelium development showed that cdc2 mRNA levels increased during aggregation and then decreased to low levels by the pseudoplasmodial stage of development. By contrast, cdc2 mRNA levels remained relatively constant as cells passed from exponential growth to the stationary phase.

Amino Acid Sequence↗
PubMed1992

Flavimonas oryzihabitans (CDC group Ve-2) bacteraemia associated with Hickman catheters.

Flavimonas oryzihabitans is a potential pathogen that may infect patients who have major medical illnesses, especially those who are undergoing surgery or have indwelling venous catheters in situ. Flavimonas oryzihabitans has been isolated from a wide range of body sites, and the portals of entry are major wounds or implanted foreign materials. We report two cases of F. oryzihabitans bacteraemia associated with the use of Hickman catheters for administration of the patients' chemotherapeutic agents. However, a common source for these infections could not be demonstrated.

Bacteremia↗
PubMed1989

The C-terminal part of a gene partially homologous to CDC 25 gene suppresses the cdc25-5 mutation in Saccharomyces cerevisiae.

In Saccharomyces cerevisiae, the product of the CDC25 gene is required for progression in the cell division cycle. It is necessary for cAMP production. It has been suggested that the CDC25 gene product acts through Ras proteins. We report the cloning of a DNA fragment from a new gene able to suppress the thermosensitive phenotype of the cdc25-5 mutation. It is unable to suppress the defect of a mutant of the adenylate cyclase gene or of the ras1, ras2ts double mutant. This DNA fragment prevents the drop in cAMP level in cdc25-5 mutant cells shifted to restrictive temperature. The complementing part of this fragment contains a truncated open reading frame (ORF) corresponding to the 3' end of a gene we named SCD25. The 584-amino acid sequence deduced from this ORF shares 45% identity with the 592-aa C-terminal part of the CDC25 ORF which is sufficient for complementation of cdc25 mutations. Some of the common sequences between these two genes are also partially homologous with the amino acid sequence of LTE1, another gene of S. cerevisiae. The capacity of the SCD25 fragment to suppress a cdc25 mutation and its homology to the C-terminal part of the CDC25 led us to propose that the CDC25 and the SCD25 C-terminal fragments each encode a protein domain which is capable in itself to support a similar biochemical function.

Amino Acid Sequence↗
PubMed1994

Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery.

Using a highly efficient viral HVJ (hemagglutinating virus of Japan) liposome-mediated transfer method, we examined the cellular fate of antisense oligodeoxyribonucleotides (oligos) in the vessel wall in vivo. Direct transfer of unmodified FITC (fluorescein isothiocyanate)-labeled oligos into injured rat carotid arteries showed, localized in the medial layer, fluorescence that disappeared within 1 day. In contrast, transfection of unmodified FITC-oligos by the HVJ-liposome method showed, concentrated in the medial layer, high levels of fluorescence that were sustained for at least 1 week. Moreover, we demonstrated nuclear localization and accumulation of fluorescence in the vessel wall using this method. To examine the therapeutic utility of this method, we transferred antisense phosphorothioate oligos against cyclin B1- and CDC2 kinase-encoding genes into balloon-injured rat carotid artery as a potential therapy for experimental restenosis. Two weeks after transfection, antisense oligo treatment directed against either CDC2 kinase or cyclin B1 resulted in a partial, but significant, inhibition in neointima formation. In contrast, transfection of either sense or scrambled control oligos had no effect. Interestingly, co-transfection of antisense oligos against CDC2 kinase and cyclin B resulted in further inhibition of neointima formation, as compared to blockade of either gene target alone. These results demonstrate that: (i) the HVJ-liposome method enhances the half life and nuclear localization of antisense oligos in the vessel wall in vivo; and (ii) HVJ-mediated administration of antisense CDC2 kinase and cyclin B1 oligos produces a sustained inhibition of neointima formation after balloon angioplasty.

Animals↗